Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Can Online Reviews Help Health Inspectors Keep Tabs on Restaurants?AHA News: Can Social Media Be Good for Your Health?Flame Retardants, Pesticides Remain Threat to U.S. Health: StudySimple Tweak to Hospital Computer Program Cuts Opioid PrescriptionsJust 2% of Patients Who Need It Get Anti-Opioid Drug NaloxoneAre Doctors Discarding 'Injured' Kidneys That Might Be Used for Transplant?Probiotics: Don't Buy the Online HypeNew Drugs Getting FDA's Blessing Faster, but Is That a Good Thing?Would Tighter Swimming Rules at Public Beaches, Lakes and Rivers Save Lives?Seniors Still Wary of Online Reviews When Picking DoctorsMany Drugstores Misinform on Disposal of Unused MedsAHA News: Get Started on the Path to Better Health in the New YearAHA News: Bystander CPR Less Common in Hispanic NeighborhoodsPrepared Bystanders Save Lives When Cardiac Arrest StrikesVaccinations Rose After California Curbed ExemptionsSpecial 'Invisible' Dye Could Serve as Skin's Vaccination RecordGrowing Obesity Rates May Contribute to Climate ChangeHealth Tip: Do's and Don'ts While Waiting for an AmbulanceFDA to Allow States to Import Prescription Drugs From Other CountriesWhere Pot Is Legal, People Are Likely to Believe Its BenefitsFewer Americans Have a Primary Care Doctor NowHospital-Level Care in Your Home? It Could Be the FutureSleepy Nurses Could Put Patients at RiskTighter Alcohol Laws Might Help Curb CancerMany Young Adults Misusing Medical Marijuana, Study SuggestsAnother Possible Effect of Climate Change: More Preemie Babies1 in 18 U.S. Teens Carries a Gun to School: StudyU.S. Poison Centers Field More Calls About Psychoactive Substances: StudyDoctors' Group Calls for Ban on Most Vaping ProductsAs Disease Outbreaks Tied to 'Anti-Vaxxers' Rise, States Take ActionAHA News: Millions Who Never Smoked Cigarettes Are Using Other Tobacco ProductsMost Docs Don't Know Hair Care Is a Barrier to Exercise for Black WomenHealth Tip: Do's and Don'ts for Calling 911Climate Change Will Hurt Kids Most, Report WarnsYou Won't Get Sued If You Do CPR, Review SuggestsRacial Bias Seen in Heart TransplantsTrump Administration Wants to Raise Age to Buy E-Cigs to 21Juul Stops Sales of Mint-Flavored E-CigarettesDo You Take Biotin Supplements? They Could Affect Your Medical TestsClimate Change a 'Threat to Human Well-Being,' Scientists SayAnti-Vaxxers Find Ways Around States' 'Personal Exemption' BansMedia Reports on Celeb Suicides Could Trigger CopycatsStill Way Too Much Smoking in Movies Aimed at KidsConsumers' Orders Changed Slightly After Calorie Counts Added to MenusReport Finds Americans' Health Is FlaggingAfter Mass Shootings, Docs Even Less Likely to Mention Gun SafetyBan on Sale of Sugary Drinks Trimmed Employees' WaistlinesAre You Accessing All Your Medical Records Online?Independent Pharmacies Are Closing Down Across the U.S.Language Barriers May Mean Repeat Visits to the Hospital
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

Maker Halts Distribution of Generic Zantac Due to Possible Carcinogen

HealthDay News
by -- Robert Preidt
Updated: Sep 19th 2019

new article illustration

THURSDAY, Sept. 19, 2019 (HealthDay News) -- Novartis, the maker of a generic form of the popular heartburn drug Zantac, said Wednesday it will cease distribution of the medicine after investigations suggested that generic and branded versions contain a known carcinogen.

A distribution halt is not the same as a full recall, and it means that generic Zantac (ranitidine) remaining on store shelves can still be sold, CBS News reported.

The move stems from an announcement made last Friday by the U.S. Food and Drug Administration. In a statement, the agency said that a substance that could cause cancer had been found in some ranitidine heartburn and ulcer medicines, including the brand name drug Zantac, and the source of this contamination is being investigated.

Sanofi, the maker of Zantac, said in a statement on Wednesday that "there are currently no plans to stop distributing or manufacturing Zantac or other ranitidine products outside of Canada," and added that "we are conducting our own robust investigations to ensure we continue to meet the highest quality safety and quality standards."

While preliminary tests found low levels of the nitrosamine impurity N-nitrosodimethylamine (NDMA) in some ranitidine products, the FDA said last week that this does not mean patients taking the drugs should now stop using them.

NDMA is the same contaminant found in many brands of blood pressure and heart failure medications during the past year, leading to recalls.

Patients who are taking prescription ranitidine who want to stop using it should discuss alternatives with their health care provider, the FDA advised. Those taking over-the-counter (OTC) ranitidine could switch to other OTC heartburn medicines.

Several drugs are approved for the same or similar uses, the FDA noted.

NDMA is an environmental contaminant found in water and foods, including meats, dairy products and vegetables. It is classified as a probable human carcinogen.

"Drug impurities remain a major national concern," said Dr. David Robbins, associate chief of endoscopy at Lenox Hill Hospital in New York City. "While Zantac may prove safe in the long run, this latest statement adds confusion and concern, so my interim advice to patients is simple: switch to another drug … and of course, confirm with your doctor the need for an antacid."

The FDA said it's evaluating whether the low levels of NDMA in ranitidine pose a risk to patients and that it will post that information when it's available.

In a statement, Sanofi said that it "takes patient safety seriously, and we are committed to working with the FDA. Zantac OTC [over the counter] has been around for over a decade and meets all the specified safety requirements for use in the OTC market."

In the meantime, Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said the FDA is working with international regulators and industry partners to find out where the contamination originated.

"The agency is examining levels of NDMA in ranitidine and evaluating any possible risk to patients," she said in a news release. "The FDA will take appropriate measures based on the results of the ongoing investigation."

Large amounts of NDMA may pose a risk, but the levels of NDMA found in ranitidine in preliminary tests barely exceed amounts found in common foods, according to the FDA.

Ranitidine decreases the amount of acid created by the stomach. OTC ranitidine is approved to prevent and relieve heartburn, and prescription ranitidine is approved for a number of uses, including treatment and prevention of ulcers of the stomach and intestines, and treatment of gastroesophageal reflux disease (GERD).

Similar contamination in heart medicines is also under investigation.

"The FDA has been investigating NDMA and other nitrosamine impurities in blood pressure and heart failure medicines called Angiotensin II Receptor Blockers [ARBs] since last year," Woodcock said. "In the case of ARBs, the FDA has recommended numerous recalls as it discovered unacceptable levels of nitrosamines."

More information

The U.S. Agency for Toxic Substances & Disease Registry has more on NDMA.




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net